Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation

Abstract

Hereditary angioedema is a rare, genetic disorder characterized by painful, debilitating and potentially life-threatening angioedema attacks in subcutaneous and submucosal tissue. While usually unpredictable, attacks can be provoked by a variety of triggers including physical injury and certain medication and are often preceded by prodromal symptoms. Hereditary angioedema has a profound influence on the patients' lives. The fundamental cause of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor. Subsequently, the contact activation cascade and kallikrein-kinin pathway are insufficiently inhibited, resulting in excessive bradykinin production triggering vascular leakage. While C1-inhibitor is an important regulator of the intrinsic coagulation pathway, fibrinolytic system and complement cascade, patients do not have an increased risk of coagulopathy, autoimmune conditions or immunodeficiency disorders. Hereditary angioedema is diagnosed based on C1-inhibitor level and function. Genetic analysis is only required in rare cases where hereditary angioedema with normal C1-inhibitor is found. In recent years, new, highly specific therapies have greatly improved disease control and angioedema-related quality of life. This article reviews the clinical picture of hereditary angioedema, the underlying pathophysiology, diagnostic process and currently available as well as investigational therapeutic options.

Keywords

hereditary angioedema - bradykinin - C1-inhibitor - contact activation - therapy

Publikationsverlauf

Artikel online veröffentlicht:
23. November 2022

• References

• 1 Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 2018; 13 (01) 73
• 2 Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119 (03) 267-274
• 3 Christiansen SC, Davis DK, Castaldo AJ, Zuraw BL. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila) 2016; 55 (10) 935-942
• 4 Hofman ZL, Relan A, Hack CE. Hereditary angioedema attacks: local swelling at multiple sites. Clin Rev Allergy Immunol 2016; 50 (01) 34-40
• 5 Hahn J, Hoess A, Friedrich DT. et al. Unnecessary abdominal interventions in patients with hereditary angioedema. J Dtsch Dermatol Ges 2018; 16 (12) 1443-1449
• 6 Landerman NS. Hereditary angioneurotic edema. I. Case reports and review of the literature. J Allergy 1962; 33: 316-329
• 7 Minafra FG, Gonçalves TR, Alves TM, Pinto JA. The mortality from hereditary angioedema worldwide: a review of the real-world data literature. Clin Rev Allergy Immunol 2022; 62 (01) 232-239
• 8 Maurer M, Magerl M, Betschel S. et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy 2022; 77 (07) 1961-1990
• 9 Caballero T, Farkas H, Bouillet L. et al; C-1-INH Deficiency Working Group. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129 (02) 308-320
• 10 Zotter Z, Csuka D, Szabó E. et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 2014; 9: 44
• 11 Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V. IOS Study Group. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol 2016; 26 (06) 383-386
• 12 Magerl M, Doumoulakis G, Kalkounou I. et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol 2014; 39 (03) 298-303
• 13 Reshef A, Prematta MJ, Craig TJ. Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. Allergy Asthma Proc 2013; 34 (03) 261-266
• 14 Leibovich-Nassi I, Reshef A, Somech R, Golander H. Prodromes as predictors of hereditary angioedema attacks. Allergy 2022; 77 (04) 1309-1312
• 15 Fouche AS, Saunders EF, Craig T. Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2014; 112 (04) 371-375
• 16 Caballero T, Aygören-Pürsün E, Bygum A. et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 2014; 35 (01) 47-53
• 17 Banerji A, Davis KH, Brown TM. et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol 2020; 124 (06) 600-607
• 18 Savarese L, Mormile I, Bova M. et al. Psychology and hereditary angioedema: a systematic review. Allergy Asthma Proc 2021; 42 (01) e1-e7
• 19 Fijen LM, Petersen RS, Levi M, Lakeman P, Henneman L, Cohn DM. Patient perspectives on reproductive options for hereditary angioedema: a cross-sectional survey study. J Allergy Clin Immunol Pract 2022; 10 (09) 2483-2486.e1
• 20 Levi M, Cohn DM. The role of complement in hereditary angioedema. Transfus Med Rev 2019; 33 (04) 243-247
• 21 Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med 2016; 48 (04) 256-267
• 22 Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med 2020; 382 (12) 1136-1148
• 23 Bossi F, Fischetti F, Regoli D. et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009; 124 (06) 1303-10.e4
• 24 Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol 2014; 121: 41-89
• 25 Wuillemin WA, Minnema M, Meijers JC. et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85 (06) 1517-1526
• 26 Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69 (02) 141-146
• 27 van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012; 167 (03) 472-478
• 28 Joseph K, Tholanikunnel TE, Kaplan AP. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol 2010; 104 (01) 50-54
• 29 Relan A, Bakhtiari K, van Amersfoort ES, Meijers JC, Hack CE. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs 2012; 26 (01) 43-52
• 30 Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 2015; 70 (05) 506-513
• 31 de Maat S, Joseph K, Maas C, Kaplan AP. Blood clotting and the pathogenesis of types I and II hereditary angioedema. Clin Rev Allergy Immunol 2021; 60 (03) 348-356
• 32 Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000; 165 (05) 2637-2642
• 33 Davis III AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol 2008; 45 (16) 4057-4063
• 34 Triggianese P, Chimenti MS, Toubi E. et al. The autoimmune side of hereditary angioedema: insights on the pathogenesis. Autoimmun Rev 2015; 14 (08) 665-669
• 35 Gösswein T, Kocot A, Emmert G. et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008; 121 (3-4): 181-188
• 36 Ponard D, Gaboriaud C, Charignon D. et al. SERPING1 mutation update: mutation spectrum and C1 Inhibitor phenotypes. Hum Mutat 2020; 41 (01) 38-57
• 37 Yasuno S, Ansai O, Hayashi R, Nakamura S, Shimomura Y. Evidence for a dominant-negative effect of a missense mutation in the SERPING1 gene responsible for hereditary angioedema type I. J Dermatol 2021; 48 (08) 1243-1249
• 38 Haslund D, Ryø LB, Seidelin Majidi S. et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema. J Clin Invest 2019; 129 (01) 388-405
• 39 Mete Gökmen N, Rodríguez-Alcalde C, Gülbahar O, Lopez-Trascasa M, Onay H, López-Lera A. Novel homozygous variants in the SERPING1 gene in two Turkish families with hereditary angioedema of recessive inheritance. Immunol Cell Biol 2020; 98 (08) 693-699
• 40 Blanch A, Roche O, Urrutia I, Gamboa P, Fontán G, López-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006; 118 (06) 1330-1335
• 41 López-Lera A, Favier B, de la Cruz RM, Garrido S, Drouet C, López-Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010; 126 (06) 1307-10.e3
• 42 Bafunno V, Divella C, Sessa F. et al. De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. J Allergy Clin Immunol 2013; 132 (03) 748-750.e3
• 43 Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis 2020; 15 (01) 289
• 44 Kulkarni M, Travers JB, Rohan C. High estrogen states in hereditary angioedema: a spectrum. Clin Rev Allergy Immunol 2021; 60 (03) 396-403
• 45 Gompel A, Fain O, Boccon-Gibod I, Gobert D, Bouillet L. Exogenous hormones and hereditary angioedema. Int Immunopharmacol 2020; 78: 106080
• 46 Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124 (01) 129-134
• 47 Tarzi MD, Hickey A, Förster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149 (03) 513-516
• 48 Bindke G, Gehring M, Wieczorek D, Kapp A, Buhl T, Wedi B. Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-/histamine-mediated angioedema. Allergy 2022; 77 (03) 946-955
• 49 Porebski G, Kwitniewski M, Reshef A. Biomarkers in hereditary angioedema. Clin Rev Allergy Immunol 2021; 60 (03) 404-415
• 50 Malbran A, Hammer CH, Frank MM, Fries LF. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol 1988; 81 (06) 1199-1204
• 51 Melamed J, Alper CA, Cicardi M, Rosen FS. The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1986; 77 (02) 322-326
• 52 Gobert D, Paule R, Ponard D. et al. A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients. Medicine (Baltimore) 2016; 95 (33) e4363
• 53 Pólai Z, Balla Z, Andrási N. et al. A follow-up survey of patients with acquired angioedema due to C1-inhibitor deficiency. J Intern Med 2021; 289 (04) 547-558
• 54 Levi M, Cohn D, Zeerleder S, Dziadzio M, Longhurst H. Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency. Allergy 2019; 74 (04) 834-840
• 55 Pappalardo E, Cicardi M, Duponchel C. et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106 (06) 1147-1154
• 56 Farkas H, Martinez-Saguer I, Bork K. et al; HAWK. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72 (02) 300-313
• 57 Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35 (02) 184-187
• 58 Agostoni A, Aygören-Pürsün E, Binkley KE. et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114 (suppl 3): S51-S131
• 59 Maurer M, Aygören-Pürsün E, Banerji A. et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol 2021; 148 (06) 1526-1532
• 60 Maurer M, Aberer W, Bouillet L. et al; IOS Investigators. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013; 8 (02) e53773
• 61 Banta E, Horn P, Craig TJ. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc 2011; 32 (04) 319-324
• 62 Craig TJ, Rojavin MA, Machnig T, Keinecke HO, Bernstein JA. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013; 111 (03) 211-215
• 63 Gadek JE, Hosea SW, Gelfand JA. et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302 (10) 542-546
• 64 Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117 (04) 904-908
• 65 Riedl MA, Bygum A, Lumry W. et al; Berinert Registry investigators. Safety and usage of C1-inhibitor in hereditary angioedema: Berinert Registry Data. J Allergy Clin Immunol Pract 2016; 4 (05) 963-971
• 66 Burnham K, Reinert JP. Thromboembolic risk of C1 esterase inhibitors: a systematic review on current evidence. Expert Rev Clin Pharmacol 2020; 13 (07) 779-786
• 67 Craig TJ, Bewtra AK, Bahna SL. et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks–final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66 (12) 1604-1611
• 68 Lumry WR, Li HH, Levy RJ. et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107 (06) 529-537
• 69 Levy RJ, Lumry WR, McNeil DL. et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104 (06) 523-529
• 70 Craig TJ, Li HH, Riedl M. et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract 2015; 3 (02) 206-212.e4
• 71 Jaffe CJ, Atkinson JP, Gelfand JA, Frank MM. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol 1975; 55 (06) 386-393
• 72 Pickering RJ, Good RA, Kelly JR, Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1 (7590): 326-330
• 73 Wentzel N, Panieri A, Ayazi M. et al. Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran. World Allergy Organ J 2019; 12 (09) 100049
• 74 Craig T, Zuraw B, Longhurst H. et al; COMPACT Investigators. Long-term outcomes with subcutaneous c1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract 2019; 7 (06) 1793-1802.e2
• 75 Lumry WR, Craig T, Zuraw B. et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract 2018; 6 (05) 1733-1741.e3
• 76 Banerji A, Riedl MA, Bernstein JA. et al; HELP Investigators. Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018; 320 (20) 2108-2121
• 77 Zuraw B, Lumry WR, Johnston DT. et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol 2021; 148 (01) 164-172.e9
• 78 Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295 (26) 1444-1448
• 79 Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett 2003; 86 (03) 271-276
• 80 Drouet C, Désormeaux A, Robillard J. et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008; 121 (02) 429-433
• 81 Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100 (02) 153-161
• 82 Craig T, Magerl M, Levy DS. et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2022; 399 (10328): 945-955
• 83 KalVista. Factor XIIa. 2022 . Accessed June 24, 2022, at: https://www.kalvista.com/products-pipeline/factor-xiia
• 84 Clermont A. Identification of novel potent oral Factor XIIa inhibitors that block kallikrein kinin system activation in a preclinical model of angioedema. Conference session presented at: EAACI Hybrid Congress; 1–3 July 2022 2022; Prague
• 85 Fijen LM, Riedl MA, Bordone L. et al. Inhibition of Prekallikrein for hereditary angioedema. N Engl J Med 2022; 386 (11) 1026-1033
• 86 OASIS-HAE. A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants with Hereditary Angioedema (HAE),. at: https://ClinicalTrials.gov/show/NCT05139810
• 87 Fijen LM, Petersen RS, Meijers JCM, Bordone L, Levi M, Cohn DM. The influence of plasma prekallikrein oligonucleotide antisense therapy on coagulation and fibrinolysis assays: a post-hoc analysis. Thromb Haemost 2022; 122 (12) 2045-2049
• 88 Maetzel A, Smith MD, Duckworth EJ. et al. KVD900, an oral on-demand treatment for hereditary angioedema: phase 1 study results. J Allergy Clin Immunol 2022; 149 (06) 2034-2042
• 89 A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE). Accessed 5 July 2022, at: https://ClinicalTrials.gov/show/NCT05259917
• 90 A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II,. Accessed 5 July 2022, at: https://ClinicalTrials.gov/show/NCT05055258
• 91 Hofman ZLM, Clark CC, Hack CE, de Maat S, Maas C. Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I study. J Allergy Clin Immunol 2020; 146 (06) 1446-1449.e5
• 92 Bista P, Nichols A. STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE. Poster presentation presented at: American Academy of Allergy, Asthma & Immunology Annual Scientific Virtual Meeting. 2022 ; Phoenix, AZ. https://astriatx.com/pdfs/Poster-02-25-22-Astria-AAAAI.pdf
• 93 Crabbé R. PHA-022121: a novel and potent bradykinin 2 receptor antagonist for oral treatment of hereditary angioedema. J Allergy Clin Immunol 2021; 147 (02) AB242
• 94 A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema at: https://ClinicalTrials.gov/show/NCT05121376
• 95 NTLA-2002 in Adults With Hereditary Angioedema (HAE). . Accessed 5 July 2022 at: https://ClinicalTrials.gov/show/NCT05120830
• 96 Orchard therapeutics. Our Portfolio and Focus. 2022 . Accessed 5 July 2022, at: https://www.orchard-tx.com/approach/pipeline/
• 97 Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343 (04) 1286-1289
• 98 Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141 (01) 31-35
• 99 Kiss N, Barabás E, Várnai K. et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 2013; 149 (01) 142-145
• 100 Bafunno V, Firinu D, D'Apolito M. et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141 (03) 1009-1017
• 101 Bork K, Wulff K, Steinmüller-Magin L. et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73 (02) 442-450
• 102 Dickeson SK, Kumar S, Sun MF. et al. A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen. Blood 2022; 139 (18) 2816-2829
• 103 Bork K, Wulff K, Rossmann H. et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy 2019; 74 (12) 2479-2481
• 104 Ariano A, D'Apolito M, Bova M. et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy 2020; 75 (11) 2989-2992
• 105 Bork K, Wulff K, Möhl BS. et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol 2021; 148 (04) 1041-1048